Thanks for the nice find, lady GoFor. That chart looks VERY interesting. It's amazing how much these top companies spend just on R&D every year - especially in THIS economy. All the more evidence that ANY one of these companies could easily "write the check" for medizone and not even blink. Even 2 BILLION for MZEI would be less than HALF of JUST THE AVERAGE that these companies spent on R&D - even in the most recent reporting period. Looking back to pre 2009 levels, acquiring MZEI would be so miniscule to them, that it MIGHT go unnoticed within the larger companies. Can you imagine how much ACQUIRING MZEI would ADD to the profit picture of said company? It has the potential to INCREASE the share price of even the larger companies by as much as 30% within the first couple of years and likely could double the share price of these smaller companies, IMO.
Another important note: THESE companies have performed SOLIDLY over the last two years as well.
Top U.S. R&D Spenders in U.S. dollars (IN MILLIONS):
Merck & Co. 8,334.3 8,425.0 6,474.0
Pfizer, Inc. 7,945.0 7,845.0 6,607.0
Johnson & Johnson 7,577.0 6,986.0 4,862.0
Lilly (Eli) & Co. 3,840.0 4,326.5 3,446.1
Bristol-Myers Squibb Co. 3,512.0 3,647.0 2,556.0
Amgen, Inc. 3,030.0 2,864.0 2,010.0
Abott Laboratories 2,688.8 2,743.7 2,667.0
Medtronic 1,335.0 1,451.0 n/a
Biogen Idec Inc. 1,072.1 1,283.1 957.8
Monsanto 1,033.0 1,113.0 938.0
Source: Battelle/R&D Magazine/Company information
News 
Market Data 
Discover 
AI
